SUBSCRIBE
SUBSCRIBE

Amylyx Pharmaceuticals

NEWS
Policy
Aduhelm Approval Draws Mixed Reaction, Sparks New Controversy Over Pricing
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
June 8, 2021
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Clinical Catch-Up: March 15-19
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
March 19, 2021
 · 
6 min read
 · 
Mark Terry
Business
BioSpace Movers & Shakers, Jan. 15
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
January 14, 2021
 · 
5 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Press Releases
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
May 7, 2026
 · 
13 min read
Press Releases
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences - May 6, 2026
May 6, 2026
 · 
1 min read
Press Releases
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
May 5, 2026
 · 
7 min read
Press Releases
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
 · 
1 min read
Press Releases
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
 · 
1 min read
Press Releases
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
March 24, 2026
 · 
7 min read
Press Releases
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
March 3, 2026
 · 
13 min read
Press Releases
Amylyx Pharmaceuticals to Participate in Upcoming March 2026 Investor Conferences
February 26, 2026
 · 
1 min read
Press Releases
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
February 25, 2026
 · 
1 min read
Press Releases
Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S
January 8, 2026
 · 
5 min read
Load More